Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Age plotted against Sept9 outcome. FP: False positive, TN: True negative, FN: False negative, TP: True positive. N: Number of subjects in each category. Age: All ages younger or equal to the age interval mentioned. -1/3 and 2/3 refers to the PCR-algorithms used

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques:

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Sept9 positivity of individuals with CRC

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques: Clinical Proteomics

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Sept9 positivity of individuals with NED

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques: Clinical Proteomics

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Predictors of Colorectal Cancer, 1/3 algorithm

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques:

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Clinicopathological data of 71 biliary tract cancer patients included in the tissue study. Associations of clinicopathological data with relative DNA methylation of SHOX2 and SEPT9 in tumor tissue

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: DNA Methylation Assay, Methylation, Biomarker Discovery

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: SHOX2 and SEPT9 DNA methylation levels in tissue samples. Relative DNA methylation values (PMR in %) of SHOX2 are depicted as black rhombuses for a NAT and BTC specimens, as well as for b NAT, CC, and GBC specimens. PMR values of SEPT9 are also depicted for c NAT and BTC specimens, as well as for d NAT, CC, and GBC specimens. Horizontal lines indicate median PMR values of sample series. p values refer to Mann-Whitney U test. *Bonferroni corrected p values for multiple pairwise compare

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: DNA Methylation Assay, MANN-WHITNEY

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves for SHOX2 , SEPT9 , and the combined biomarker panel (based on the sum of PMR values) in tissue specimens. The ROC curves and resulting area under the curve (AUC) values are depicted for a all 55 BTC specimens: AUC— SHOX2 = 0.918 [95% CI 0.865–0.971]; AUC— SEPT9 = 0.601 [95% CI 0.488–0.713]; AUC—Panel 0.933 [95% CI 0.886–0.979] b 43 CC specimens: AUC— SHOX2 = 09.21 [0.863–0.979]; AUC— SEPT9 = 0,.541 [95% CI 0.416–0.666]; AUC—Panel = 0.932 [95% CI 0.880–0.984] and c 12 GBC specimens: AUC— SHOX2 = 0.907 [95% CI 0.808–1.005]; AUC— SEPT9 = 0.815 [95% CI 0.637–0.993]; AUC—Panel = 0.935 [95% CI 0.855–1.015], respectively

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Biomarker Discovery

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Results from univariate and multivariate survival analyses (Cox proportional hazard models)

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Biomarker Discovery, Methylation

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Relative DNA methylation values (PMR in %) of a SHOX2 and b SEPT9 in plasma samples from 100 controls and 20 cholangiocarcinoma patients. Each black rhombus represents a patient sample. Horizontal lines indicate median PMR values of sample series. p values refer to Mann-Whitney U test

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: DNA Methylation Assay, Clinical Proteomics, MANN-WHITNEY

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves and area under the curve (AUC) values for SHOX2 , SEPT9 , and the combined biomarker panel, based on the sum of PMR values, in plasma samples. AUC— SHOX2 = 0.691 [95% CI 0.554–0.828]; AUC- SEPT9 = 0.699 [95% CI 0.561–0.837]; AUC-Panel = 0.752 [95% CI 0.631–0.873]

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Biomarker Discovery, Clinical Proteomics